You are here: Home » News-CM » Companies » News
Business Standard

Zydus Cadila receives final approval for Diflunisal Tablets

Capital Market 

From USFDA

Zydus Cadila has received final approval from USFDA to market Diflunisal Tablets in the strengths of 500 mg. It is a nonsteroidal anti-inflammatory drug (NSAID) and will be produced at the group's formulations manufacturing facility at Baddi.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Tue, June 20 2017. 10:30 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU